NTLA (US) share price forecast & AI signal — Intellia Therapeutics, Inc
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in NTLA
Intellia Therapeutics, Inc is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a SELL with high confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Intellia Therapeutics, Inc
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and...
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $11.35 |
| 2026-11-05 | $11.10 |
| 2026-11-04 | $12.31 |
| 2026-11-03 | $11.86 |
| 2026-11-02 | $11.66 |
| 2026-10-30 | $12.47 |
| 2026-10-29 | $13.23 |
NTLA FAQ
Is Intellia Therapeutics, Inc (NTLA) a buy or sell this week?
The ACE Stock Bots machine-learning model rates NTLA a SELL for the week of 2026-10-30 with high confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for NTLA?
Every week the model scores NTLA across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.